ARA-290

Peptide

Eleven-amino-acid erythropoietin-derived peptide designed to activate the innate repair receptor without erythropoiesis. Small exploratory trials studied neuropathy outcomes; no approved consumer indication or dosing standard exists.

Pharmacokinetic model

A route-level PK model for ara-290 is being prepared from published data. Dosing references, studies, and documented interactions are below; the app catalog is updated as models are validated.

Key facts

Category: Peptide
Suggested cadence: once daily

Research behind this entry

Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study Heij L, Niesters M, Swartjes M, Hoitsma E, Drent M, Dunne A, Grutters JC, Vogels O, Brines M, Cerami A, Dahan A · Molecular Medicine, 2012 DOI
Exploratory trial randomized 22 sarcoidosis patients to IV ARA-290 or placebo for four weeks. It reported symptom signals without safety concerns, but the small pilot was not definitive.
ARA 290, a Nonerythropoietic Peptide Engineered from Erythropoietin, Improves Metabolic Control and Neuropathic Symptoms in Patients with Type 2 Diabetes Brines M, Dunne AN, van Velzen M, Proto PL, Ostenson CG, Kirk RI, Petropoulos IN, Javed S, Malik RA, Cerami A, Dahan A · Molecular Medicine, 2014 DOI
Small phase 2 trial compared 4 mg SC daily with placebo for 28 days in type 2 diabetes and painful neuropathy. Several metabolic and symptom measures favored ARA-290, while other neuropathy measures did not; larger…

2 published studies referenced in the app, each with a plain-language summary.